Del. drugmaker gets $33M funding boost

10/4/2013 | BioWorld (free content)

Loxo Oncology secured $33 million in a Series A financing round from new and existing investors. The firm will use the money to advance its lead compound through proof-of-concept studies and move another through clinical development stage over roughly the next three years. A recent deal potentially worth $434 million between Loxo and Array BioPharma helped pique interest in the funding round.

View Full Article in:

BioWorld (free content)

Published in Brief:

SmartBrief Job Listings for Health Care